Topical and systemic antifungal agents.
Superficial fungal infections are frequent and can cause considerable morbidity. Many topical agents are available that are effective against most of these infections. Systemic fungal infections are increasing in frequency, especially among immunocompromised hosts. Amphotericin B remains the most important therapeutic agents but is associated with significant acute and chronic toxicities.
Bodey
G P
GP
Department of Medical Specialities, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston.
D000287:Administration, Topical; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy*; D005437:Flucytosine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects / Q000627:therapeutic use; D008825:Miconazole / Q000009:adverse effects / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine; D007654:Ketoconazole